Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy

Patent metadata

Field	Value
Publication number	US-9539323-B2
Application number	US-201113814614-A
Country	US
Kind code	B2
Filing date	Aug 5, 2011
Priority date	Aug 6, 2010
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.

First claim

What is claimed is:

1. A method of treating or prophylactically treating a subject having cancer, said method comprising administering to said subject a malic enzyme 2 inhibitor in an amount sufficient to treat said cancer, wherein the malic enzyme 2 inhibitor is an RNAi agent or antisense oligonucleotide that comprises any one of SEQ ID NOs:1-36.

2. The method of claim 1 , wherein said cancer is selected from the group consisting of leukemia, breast cancer, and skin cancer.

3. The method of claim 2 , wherein said cancer is leukemia and said leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.

4. The method of claim 1 , wherein said cancer is lung cancer and said lung cancer is selected from the group consisting of non-small cell lung cancer, small-cell lung cancer, carcinoid, sarcoma, squamous cell cancer, adenocarcinoma, and large cell carcinoma.

5. The method of claim 1 , wherein said method further comprises administering to said subject an anticancer agent and wherein said malic enzyme 2 inhibitor and said anticancer agent are together in an amount sufficient to treat said cancer.

6. The method of claim 5 , wherein said anticancer agent is one or more of a chemotherapeutic agent, an immunomodulatory agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analog, a DNA intercalating agent, a topoisomerase analog, or a folate antimetabolite.

7. The method of claim 6 , wherein said anticancer agent is said chemotherapeutic agent selected from the group consisting of cisplatin, carboplatin, chlorambucil, melphalan, nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, imatinib, nilotinib, dasatinib, and radicicol.

8. A method of treating or prophylactically treating a subject having cancer, said method comprising administering to said subject a malic enzyme 2 inhibitor comprising a nucleic acid sequence identical to the sequence of any one of SEQ ID NOs:1-36 in an amount sufficient to treat said cancer.

9. The method of claim 8 , wherein said cancer is selected from the group consisting of leukemia, brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, stomach cancer, testis cancer, thyroid cancer, and urothelial cancer.

10. The method of claim 9 , wherein said cancer is leukemia and said leukemia is selected from the group consisting of chronic myeloid leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.

11. The method of claim 9 , wherein said cancer is lung cancer and said lung cancer is selected from the group consisting of non-small cell lung cancer, small-cell lung cancer, carcinoid, sarcoma, squamous cell cancer, adenocarcinoma, and large cell carcinoma.

12. The method of claim 8 , wherein said method further comprises administering to said subject an anticancer agent and wherein said malic enzyme 2 inhibitor and said anticancer agent are together in an amount sufficient to treat said cancer.

13. The method of claim 12 , wherein said anticancer agent is one or more of a chemotherapeutic agent, an immunomodulatory agent, an antiangiogenic agent, a mitotic inhibitor, a nucleoside analog, a DNA intercalating agent, a topoisomerase analog, or a folate antimetabolite.

14. The method of claim 13 , wherein said anticancer agent is a chemotherapeutic agent selected from the group consisting of cisplatin, carboplatin, chlorambucil, melphalan, nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, imatinib, nilotinib, dasatinib, and radicicol.

Assignees

• Sukhatme Vikas P
• Ren Jian-Guo
• Beth Israel Deaconess Medical Ct Inc

Inventors

• Sukhatme Vikas P
• Ren Jian-Guo

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/336

  having three-membered rings, e.g. oxirane, fumagillin · CPC title

• C12N15/1137

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title